Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5

Benzinga · 1d ago
Chardan Capital analyst Andreas Argyrides initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Neutral rating and announces Price Target of $1.5.